{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T15:00:24Z","timestamp":1785078024031,"version":"3.55.0"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108289","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:27:57Z","timestamp":1781206077000},"page":"108289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Interpreting the CHANGING trial: Methodological considerations and the need for cautious framing"],"prefix":"10.1016","volume":"230","author":[{"given":"Lixin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Massironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoku","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108289_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108176","article-title":"Efficacy of Chinese medicine WW-1 in managing gastric atrophy and intestinal metaplasia in patients with chronic atrophic gastritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"227","author":"Yang","year":"2026","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108289_bib2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.gie.2009.12.029","article-title":"The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis","volume":"71","author":"Capelle","year":"2010","journal-title":"Gastrointest. Endosc."},{"issue":"2","key":"10.1016\/j.phrs.2026.108289_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2478\/raon-2024-0028","article-title":"Pathogenesis and potential reversibility of intestinal metaplasia - a milestone in gastric carcinogenesis","volume":"58","author":"Drnovsek","year":"2024","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.phrs.2026.108289_bib4","first-page":"R1","article-title":"Addendum on estimands and sensitivity analysis in clinical trials","volume":"9","author":"Guideline","year":"2017","journal-title":"Clin. Trials"},{"issue":"4","key":"10.1016\/j.phrs.2026.108289_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/a-0859-1883","volume":"51","author":"Pimentel-Nunes","year":"2019","journal-title":"Endoscopy"},{"issue":"4","key":"10.1016\/j.phrs.2026.108289_bib6","first-page":"512","article-title":"National Medical Products Administration. Technical Guideline for Clinical Efficacy Evaluation of Traditional Chinese Medicine New Drugs Used in Chronic Gastritis (Trial). Notice No. 47, 2022","volume":"39","author":"Center for Drug Evaluation","year":"2023","journal-title":"Chin. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108289_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11655-015-2114-5","article-title":"Randomized double-blind clinical trial of Moluodan for the treatment of chronic atrophic gastritis with dysplasia","volume":"22","author":"Tang","year":"2016","journal-title":"Chin. J. Integr. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:03:59Z","timestamp":1785074639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":7,"alternative-id":["S1043661826002045"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108289","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interpreting the CHANGING trial: Methodological considerations and the need for cautious framing","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108289"}}